Columbia Care Statement on New Jersey Adult-Use Cannabis Reform Bills

February 23, 2021

NEW YORK, N.Y., February 23, 2021 – Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”) released the following statement from CEO Nicholas Vita following the signing of cannabis legislation by New Jersey Governor Phil Murphy.  

“We commend New Jersey Governor Phil Murphy and the state legislature for coming together to pass a series of cannabis reform bills that not only reflect the will of the voters but that also take historic action to lift up communities that have been disproportionately impacted by the failed prohibition of cannabis. We look forward to working closely with the Cannabis Regulatory Commission (CRC) to support the expansion of the existing medical market framework to adult use and ensuring that patients across the state continue to have equal access to the cannabis products they trust and need to treat many chronic conditions. As an existing medical operator, we have made substantial investments in New Jersey and its medical market, bringing trusted and quality products to patients and creating an infrastructure to support the growing market. We have already begun to expand our existing cultivation operations to meet the growing patient demand and are in a strong position to accommodate adult use customers when sales begin. We welcome the opportunity to bring the same level of product integrity to help all adults on their health and wellness journeys. This is a landmark day for New Jersey, and we look forward to playing a part in the success of the roll-out in the days and months to come.”

About Columbia Care

Columbia Care is one of the largest and most experienced cultivators, manufacturers and providers of medical and adult use cannabis products and related services with licenses in 18 US jurisdictions and the EU. Columbia Care currently operates 108 facilities including 81 dispensaries and 27 cultivation and manufacturing facilities. Columbia Care is one of the original providers of medical cannabis in the United States, and continues to deliver an industry-leading, patient-centered medicinal cannabis operation that has quickly expanded into the adult use market as a premier operator. The company currently offers products spanning flower, edibles, oils, and tablets, and manufactures popular brands including Seed & Strain, Amber and Platinum Label CBD. With more than four million sales transactions since its inception in 2012, Columbia Care is known for setting the standard for compassion, professionalism, quality, care, and innovation in the rapidly expanding cannabis industry. For more information on Columbia Care, please visit www.col-care.com.

Caution Concerning Forward-Looking Statements

This press release contains certain statements that constitute forward-looking information within the meaning of applicable securities laws and reflect the Company’s current expectations regarding future events. The Company has made assumptions with regard to the expansion of its Boston dispensary, which  although considered reasonable by the Company at the time of preparation, may prove to be incorrect, as well as other risk factors discussed under “Risk Factors” in Columbia Care’s Annual

Information Form dated March 31, 2020, filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com and described from time to time in documents filed by the Company with Canadian securities regulatory authorities.

+